{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:24:20Z","timestamp":1764689060378,"version":"3.40.5"},"reference-count":38,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Theravance Biopharma, Inc.","award":["TLV-2014-024"],"award-info":[{"award-number":["TLV-2014-024"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Telavancin is a lipoglycopeptide with potent activity against methicillin-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n            (MRSA) and methicillin-susceptible\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n            (MSSA). The activity of telavancin against MRSA and MSSA after prior vancomycin exposure was studied in an\n            <jats:italic>in vitro<\/jats:italic>\n            pharmacodynamic model. Two clinical MRSA and two MSSA isolates, all with vancomycin MICs of 2 \u03bcg\/ml, were subjected to humanized free drug exposures of vancomycin at 1 g every 12 h (q12h) for 96 h, telavancin at 750 mg q24h for 96 h, and vancomycin at 1 g q12h for 72 h followed by telavancin at 750 mg q24h for 48 h (120 h total). The microbiological responses were measured by changes from 0 h in log\n            <jats:sub>10<\/jats:sub>\n            CFU\/ml at the end of experiments and area under the bacterial killing and regrowth curves over 96 h (AUBC\n            <jats:sub>0\u221296<\/jats:sub>\n            ). The control isolates grew to 8.8 \u00b1 0.3 log\n            <jats:sub>10<\/jats:sub>\n            CFU\/ml. Initially, all regimens caused \u22124.5 \u00b1 0.9 reductions in log\n            <jats:sub>10<\/jats:sub>\n            CFU\/ml by 48 h followed by slight regrowth over the following 48 to 72 h. After 96 h, vancomycin and telavancin achieved \u22123.7 \u00b1 0.9 and \u22123.8 \u00b1 0.8 log\n            <jats:sub>10<\/jats:sub>\n            CFU\/ml changes from baseline, respectively (\n            <jats:italic>P<\/jats:italic>\n            = 0.74). Sequential exposure to telavancin after vancomycin did not result in additional CFU reductions or increases, with ultimate log\n            <jats:sub>10<\/jats:sub>\n            CFU\/ml reductions of \u22124.3 \u00b1 1.1 at 96 h and \u22124.2 \u00b1 1.3 at 120 h (\n            <jats:italic>P<\/jats:italic>\n            &gt; 0.05 for all comparisons at 96 h). The AUBC\n            <jats:sub>0\u201396<\/jats:sub>\n            was significantly smaller for the regimen of telavancin for 96 h than for the regimens of vancomycin for 96 h and vancomycin followed by telavancin (\n            <jats:italic>P<\/jats:italic>\n            \u2264 0.04). No resistance was observed throughout the experiment. Against these MRSA and MSSA isolates with vancomycin MICs of 2 \u03bcg\/ml, telavancin was comparable with vancomycin and its activity was unaffected by prior vancomycin exposure.\n          <\/jats:p>","DOI":"10.1128\/aac.02033-15","type":"journal-article","created":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T12:34:21Z","timestamp":1445344461000},"page":"222-228","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":5,"title":["<i>In Vitro<\/i>\n            Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure"],"prefix":"10.1128","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-9094","authenticated-orcid":false,"given":"Abrar K.","family":"Thabit","sequence":"first","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA"},{"name":"Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA"},{"name":"Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph L.","family":"Kuti","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kws273"},{"key":"e_1_3_2_3_2","volume-title":"Antibiotic resistance threats in the United States","author":"Centers for Disease Control and Prevention","year":"2013","unstructured":"Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. Centers for Disease Control and Prevention, Atlanta, GA."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.10423"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/502522"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.3410\/M4-4"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.05.031"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1581-1585.2006"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01516-13"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl235"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00062-10"},{"key":"e_1_3_2_12_2","volume-title":"Vibativ (telavancin) for injection prescribing information","author":"Theravance Inc","year":"2014","unstructured":"Theravance Inc. 2014. Vibativ (telavancin) for injection prescribing information. Theravance, Inc., South San Francisco, CA."},{"key":"e_1_3_2_13_2","volume-title":"Document M100-S24","author":"Clinical and Laboratory Standards Institute","year":"2014","unstructured":"Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing: 24th informational supplement. Document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_14_2","volume-title":"Cubicin (daptomycin) for injection prescribing information","author":"Cubist Inc","year":"2014","unstructured":"Cubist Inc. 2014. Cubicin (daptomycin) for injection prescribing information. Cubist, Inc., Lexington, MA."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)07324-8"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.4.399"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01885.x"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05915-11"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809102500701"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05473-11"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/bms128"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq113"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00857-10"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr234"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q331"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00676-12"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq031"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2008.05.012"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2012.669843"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00773-15"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.02.007"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01544-08"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05849-11"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.060640-0"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03172-14"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00933-10"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.11.001"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01653-13"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00712-11"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02033-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02033-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:28:08Z","timestamp":1645475288000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02033-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1128\/AAC.02033-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.02033-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"2015-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-10-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}